Bharat Biotech (India)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 433 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +6

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 360 citations · Full text

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 358 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial

Nita Bhandari, Temsunaro Rongsen‐Chandola, Ashish Bavdekar et al. · The Lancet · 2014 · 317 citations · Full text

Vaccination, Vaccine Safety, Veterinary Vaccine +9

Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study

Vineeth Varanasi, Anit Singh, Marcela F. Pasetti et al. · Clinical Infectious Diseases · 2015 · 199 citations · Full text